 Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 depsipeptide IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study. 